Skip to content

Clinical study on changes in gut microbiota and the effect of bifidobacterium administration in postoperative patients with esophageal cancer

Clinical study on changes in gut microbiota and the effect of bifidobacterium administration in postoperative patients with esophageal cancer - Clinical study on bifidobacterium administration in esophageal cancer patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000048189
Enrollment
15
Registered
2022-06-29
Start date
2022-06-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

One sachet of bifidobacterium powder is administered in the evening of the first postoperative day. From the second to the seventh postoperative day, One sachet of bifidobacterium powder is administer

Sponsors

Nagoya City University Graduate School of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients with stage 2 and 3 esophageal cancer who are scheduled to undergo esophagectomy. 2) Patients who are scheduled to start enteral nutrition according to the clinical pathway of this hospital after surgery. 3) Patients with or without preoperative chemotherapy 4) Patients with or without multiple cancers 5) Patients 20 years of age or older 6) Patients who can obtain informed consent from the patient

Exclusion criteria

Exclusion criteria: 1) Patients with Performance Status of 3 or higher 2) Patients with serious complications such as poorly controlled diabetes mellitus or hypertension 3) Patients with muscle diseases including active myopathy or muscular dystrophy 4) Patients who are pregnant or lactating 5) Patients who participated in clinical trial or clinical research involving the use of an unapproved drug and received an investigational drug or unapproved drug at least 16 weeks prior to the informed consent 6) Patients who are determined to be ineligible for this study by the principal investigator or subinvestigator 7) Patients who are allergic to the study food 8) Patients who failed to obtain informed consent or withdrew informed consent

Design outcomes

Primary

MeasureTime frame
abundance of proteobacteria in feces

Secondary

MeasureTime frame
1) Species and diversity score of gut microbiota 2) Gastrointestinal symptoms after surgery 3) Frequency and severity of infectious complications 4) Frequency and severity of other postoperative complications 5) Length of hospital stay after surgery 6) Nutritional intake 7) Blood test

Countries

Japan

Contacts

Public ContactRyo Ogawa

Nagoya City University Graduate School of Medical Sciences Gastroenterological Surgery

r-ogawa@med.nagoya-cu.ac.jp052-853-8226

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026